Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:hasAssay |
gptkb:human
binding |
| gptkbp:hasBiologicalActivity |
inhibitor
|
| gptkbp:hasInChIKey |
QZQKZQJQZQJQJQ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H19N3O3S
|
| gptkbp:hasSMILES |
CN1C=CC2=C1C=CC(=C2)C3=CC(=O)NC(=O)C3S
|
| gptkbp:hasStandardType |
IC50
|
| gptkbp:hasStandardValue |
0.6 μM
|
| https://www.w3.org/2000/01/rdf-schema#label |
CHEMBL1201582
|
| gptkbp:molecularWeight |
345.42
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201582
25185398 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:supportsDatabase |
gptkb:ChEMBL
gptkb:PubChem |
| gptkbp:synonym |
gptkb:GSK-3_inhibitor_VIII
gptkb:3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione |
| gptkbp:target |
gptkb:Glycogen_synthase_kinase-3_beta
|
| gptkbp:therapeuticArea |
gptkb:diabetes
central nervous system |
| gptkbp:bfsParent |
gptkb:Leptin
|
| gptkbp:bfsLayer |
6
|